Related Experiment Videos
Organizing pneumonia after rituximab therapy: Two cases
Martin Soubrier1, Gaëlle Jeannin, Jean Louis Kemeny
1Rheumatology Department, Gabriel Montpied Teaching Hospital, Clermont-Ferrand, France. msoubrier@chu-clermontferrand.fr
Joint Bone Spine
|April 22, 2008
Summary
Rituximab, a CD20-targeting antibody, can cause rare lung toxicity. Organizing pneumonia, sometimes asymptomatic, was seen in 2 of 25 patients, suggesting routine chest X-rays before retreatment.
Area of Science:
- Immunology
- Pulmonology
- Oncology
Background:
- Rituximab is a chimeric monoclonal antibody targeting CD20, widely used in treating various autoimmune diseases and cancers.
- While generally safe, rituximab has been associated with rare instances of pulmonary toxicity.
- Reported lung toxicities include infiltrates, alveolar hemorrhage, and adult respiratory distress syndrome.
Observation:
- Organizing pneumonia (formerly bronchiolitis obliterans with organizing pneumonia or BOOP) is a rare manifestation of rituximab-induced lung toxicity.
- A review of 25 patients treated with rituximab for rheumatoid arthritis and Castleman's disease revealed two cases of organizing pneumonia.
- One documented case of organizing pneumonia was asymptomatic, highlighting the potential for subclinical disease.
Findings:
- The incidence of organizing pneumonia in this cohort was 8% (2 out of 25 patients).
- The development of organizing pneumonia did not appear to be solely linked to a specific underlying condition (RA vs. Castleman's disease).
- Asymptomatic presentation underscores the challenge in early diagnosis.
Implications:
- Routine chest radiography prior to rituximab re-treatment is recommended to detect subclinical organizing pneumonia.
- Early detection of organizing pneumonia may allow for timely intervention and potentially mitigate further lung damage.
- This finding contributes to the understanding of rare adverse events associated with rituximab therapy.
Related Concept Videos
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:27Pneumothorax-II
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
01:28Pleural Effusion II: Symptoms and Management
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:30Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...